<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331743</url>
  </required_header>
  <id_info>
    <org_study_id>PLM60-HCC-201901/PRO</org_study_id>
    <nct_id>NCT04331743</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC</brief_title>
  <official_title>A Single-arm, Open-label, Single-center Phase Ib Study to Evaluate the Safety and Efficacy of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose escalation study based on 3+3 design with the aim to establish MTD and provide
      RP2D. PLM60 is to administered by multi-cycle intravenous infusion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limited toxicity (DLT)</measure>
    <time_frame>1year</time_frame>
    <description>To identify the dose-limited toxicity (DLT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>1 year</time_frame>
    <description>To identify the maximum tolerated dose (MTD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II Dose (RP2D)</measure>
    <time_frame>1 year</time_frame>
    <description>To identify the Recommended Phase II Dose (RP2D)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>2 years</time_frame>
    <description>To preliminarily evaluate the AUC in patients with advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>2 years</time_frame>
    <description>To preliminarily evaluate Cmax in patients with advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak plasma concentration (Tmax)</measure>
    <time_frame>2 years</time_frame>
    <description>To preliminarily evaluate Tmax in patients with advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>To preliminarily evaluate ORR in patients with advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>To preliminarily evaluate PFS in patients with advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>To preliminarily evaluate ORR in patients with advanced HCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>2 years</time_frame>
    <description>To preliminarily evaluate DoR in patients with advanced HCC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>PLM60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three dose levels will be tested according to the &quot;3 + 3&quot; dose-escalation design.The dose-limiting toxicity (DLT) will be assessed from the first administration of PLM60 to the end of the first cycle (28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposome-entrapped Mitoxantrone Hydrochloride Injection</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>PLM60</arm_group_label>
    <other_name>PLM60</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent from the patient；

          -  ECOG performance status of 0 or 1;

          -  Histologically/cytologically confirmed diagnosis of advanced HCC;

          -  Adequate washout period for previous anti-tumor therapy;

          -  Measurable disease according to RECIST v1.1;

          -  Life expectancy ≥ 12 weeks;

          -  Adequate organ function;

          -  Child-Pugh grade A or partial grade B; BCLC stage B or C;V

        Exclusion Criteria:

          -  Prior treatment with Mitoxantrone or Liposome-entrapped Mitoxantrone, or other
             anthracyclines, with the total cumulative dose of ＞ 360 mg/m2 ;

          -  Any drug-related adverse event derived from any previous anti-tumor treatment,
             excluding alopecia, Pigmentation, or other toxicity with little safety risk for
             subjects, that has not recovered to grade1 or less;

          -  Active central nervous system (CNS) metastases (brain or leptomeningeal metastases,
             etc.);

          -  Any history of other malignancy within 5 years;

          -  Untreated hepatitis infection;

          -  HIV positive;

          -  History of liver transplantation, severe cirrhosis, hepatic encephalopathy;

          -  Inadequate cardiac function;

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kun Lou</last_name>
    <phone>0311-67808817</phone>
    <email>loukun@mail.ecspc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xuefang Xia</last_name>
    <phone>010-63930702</phone>
    <email>xiaxuefang@mail.ecspc.com</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

